Rufinamide

• UNSPSC Description:

  Rufinamide (E 2080; CGP 33101; RUF 331) is a novel anticonvulsant compound that can be used in the research of Lennox-Gastaut syndrome.

• Target Antigen:

  Sodium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/rufinamide.html

• Purity:

  99.88

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CN(CC2=C(F)C=CC=C2F)N=N1)N

• Molecular Weight:

  238.19

• References & Citations:

  [1]Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72.|[2]White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  106308-44-5